CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia Wagner(Washington University in St. Louis), Todd A. Fehniger(Washington University in St. Louis), Jeffrey Leong(Washington University in St. Louis), Maximillian Rosario(Washington University in St. Louis), Brea A. Jewell(Washington University in St. Louis), Michelle Becker‐Hapak(Washington University in St. Louis), Sara Abdel-Latif(Washington University in St. Louis), Jodie P. Goodridge(Fate Therapeutics (United States)), Justin King(Washington University in St. Louis), Timothy Schappe(Washington University in St. Louis), Rizwan Romee(Washington University in St. Louis), Karl‐Johan Malmberg(Karolinska University Hospital), Dennis Clement(Oslo University Hospital), Stephanie E. Schneider(Washington University in St. Louis), Aaron R. Ireland(Washington University in St. Louis), Hing C. Wong(Heat Biologics (United States)), Devika Jaishankar(Washington University in St. Louis), Melissa M. Berrien-Elliott(Washington University in St. Louis), Ryan Sullivan(Washington University in St. Louis), Ravi Vij(Washington University in St. Louis)
Cited by 311
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
|Immunity|2007|988
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695